The molecular epidemiology of incident methicillin-resistant Staphylococcus aureus cases among hospitalized patients in Alberta, Canada: a retrospective cohort study by Kathryn Bush et al.
RESEARCH Open Access
The molecular epidemiology of incident
methicillin-resistant Staphylococcus aureus
cases among hospitalized patients in Alberta,
Canada: a retrospective cohort study
Kathryn Bush1, Jenine Leal1, Sumana Fathima2, Vincent Li2, David Vickers1, Linda Chui2,3, Marie Louie2,4,
Geoffrey Taylor1,5 and Elizabeth Henderson1,6*
Abstract
Background: Infection Prevention and Control (IPC) surveillance for incident methicillin-resistant Staphylococcus
aureus (MRSA) in hospitalized patients is performed in a complete provincial surveillance network of all acute care
facilities in Alberta, Canada. IPC surveillance is centralized using a web-based data entry platform so that each patient is
counted only once. All diagnostic laboratories submit the first clinical MRSA isolate associated with a patient without
previous MRSA positive clinical cultures in the preceding year to the Provincial Laboratory for Public Health (ProvLab)
for molecular typing. This study will investigate the relationship between the IPC epidemiological classification based
on time of detection following admission to hospital (Hospital Acquired and Community Associated) and the matched
laboratory MRSA surveillance data using a retrospective cohort study design.
Methods: Incident IPC MRSA cases were classified according to IPC epidemiologic definitions. DNA sequencing of
the Staphylococcus protein A (spa) gene and pulsed-field gel electrophoresis (PFGE) typing was performed. IPC
MRSA surveillance data were matched to the ProvLab molecular surveillance data. Univariate comparisons of
proportions were performed for categorical variables and the Student’s t test for continuous variables.
Results: MRSA molecular typing data were available for matching for 46.7 % (2248/4818) of incident IPC cases.
There was agreement in definitions for traditional nosocomial clones (USA100/CMRSA2) with Hospital Acquired
(HA)-MRSA (65.1 % of all IPC HA-MRSA) and traditional community clones (USA400/CMRSA7 and USA300/CMRSA10)
with Community Acquired (CA)-MRSA (62.4 % of CA-MRSA). However, we observed discordance for both traditional
nosocomial/CA-MRSA (30.4 % of CA-MRSA) and for traditional community/HA-MRSA (26.9 % of HA-MRSA).
Conclusions: We note agreement between traditional nosocomial clones and HA-MRSA, and traditional community
clones and CA-MRSA. However, approximately one-quarter of HA-MRSA are those of traditional community clones
while approximately one-third of CA-MRSA are those of traditional nosocomial clones. Collaborative provincial MRSA
surveillance is important as the distinction between IPC case attribution in acute care settings and the historical
definitions of MRSA clones as community- or healthcare-associated have blurred.
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Background
Methicillin-resistant Staphylococcus aureus (MRSA) is
a major cause of healthcare-associated infections. In
Canada there are ten recognized epidemic types of
MRSA based on pulsed-field gel electrophoresis (PFGE)
patterns (CMRSA1–10) [1]. In Canadian healthcare fa-
cilities, MRSA strains associated with the USA100/
CMRSA2 clone have predominated [2]. However, trad-
itionally community-associated USA400/CMRSA7 and
USA300/CMRSA10 clones are becoming more common
in the healthcare setting [3]. Reports on the epidemiology
of MRSA have described the blurring in the definitions of
traditional nosocomial- and traditional community-MRSA
clones [3–6].
Surveillance for healthcare-associated infections is a
mandate for Infection Prevention and Control (IPC) pro-
grams to establish baseline frequency of disease, identify
risk factors, measure the impact of prevention initiatives,
and provide information to inform and educate healthcare
workers [6]. Surveillance is most successful when it is
comprehensive and linked to program objectives so that
surveillance reports are timely and subsequent actions are
meaningful and addressed [7].
The IPC program in Alberta, Canada conducts surveil-
lance of healthcare-associated infections in a complete
network with participation from every acute care facility
in the province. The IPC surveillance program uses
epidemiological definitions based on time to detection of
the MRSA from the admission date of the patient to the
facility. These definitions categorize the incident MRSA as
community or healthcare-related. An incident IPC case
can include a colonized or an infected patient.
A core function of the Provincial Laboratory for Public
Health (ProvLab) is laboratory surveillance, which includes
the identification of emerging problems, reporting strat-
egies, dissemination of information and other intervention
programs for infectious diseases. MRSA is a notifiable
pathogen in Alberta and molecular typing of first clinical
MRSA isolate in a patient in the preceding 12 months has
been performed at the ProvLab since June 2005 [4]. Histor-
ically, MRSA typing in Alberta has used pulsed-field gel
electrophoresis (PFGE) types however in March 2010
Staphylococcus aureus protein A (spa) typing was
implemented, with standardized nomenclature that
allows for easy international comparisons [8].
In this paper we discuss the molecular epidemiology of
MRSA cases detected by an extensive, collaborative surveil-
lance network in the Canadian province of Alberta.
Methods
Study population
The province of Alberta, Canada had a population of
3,785,597 in 2011 in a total geographic area of 661,190
square kilometers. Most (68.5 %) of the population reside
in geographic areas surrounding two major urban centers:
Calgary (2011 population 1,408,606; 37.2 % of the provin-
cial total) and Edmonton (1,186,121; 31.3 %). Created in
2009, Alberta Health Services (AHS) provides the majority
of healthcare in the province along with a partner provider
agency, Covenant Health (COV). AHS/COV provided
2,985,493 hospital patient-days across all hospital facilities
in 2011 (40.4 % in the Edmonton zone, 28.7 % in the Cal-
gary zone).
Ethics statement
IPC conducts mandatory surveillance to monitor healthcare-
associated infections in all acute care facilities in the prov-
ince. A Project Ethics Community Consensus Initiative
was completed. Based upon six ethical considerations, the
project was deemed to be under the IPC mandate for
quality improvement and approved to meet ethical stan-
dards; written consent was not required for this analysis.
The project data were collected in the provincial IPC sur-
veillance database in patient identified form, however, for
analysis all data were deidentified and project results are
presented in aggregate format. Existing privacy impact
agreements between the ProvLab and Alberta Health Ser-
vices enabled analysis of patient-level data.
Surveillance network
Infection Control Professionals in AHS/COV began moni-
toring MRSA in admitted patients at all acute care facilities
in Alberta on April 1, 2011 by reviewing all positive labora-
tory cultures from hospitals throughout the province. Pro-
vincial IPC surveillance is based on national surveillance
protocols. An incident MRSA case is defined as the first
time a patient has a confirmed positive MRSA culture from
a screening or clinical specimen while admitted to an AHS/
COV acute care facility. IPC surveillance is centralized
using a web-based data entry platform and patient transfers
in all acute care facilities are monitored so that each patient
is counted only once. Infection Control Professionals re-
view patient charts to collect epidemiologic data to classify
the MRSA. Patients in acute care hospitals in Alberta are
screened for MRSA according to provincial guidelines [9].
All acute care laboratories submit the first clinical
MRSA isolate associated with a patient without previous
MRSA positive clinical cultures in the preceding year to
ProvLab for molecular typing.
IPC MRSA classification
An acute care patient who is newly identified with MRSA
is an incident IPC case and is classified based on the follow-
ing criteria as has been described [10]: HA-MRSA identi-
fied more than 48 h after admission; HCA within 48 h after
admission AND healthcare risk factors (such as Long Term
Care resident or renal patient); CA-MRSA within 48 h after
admission and does not fulfill criteria for HA or HCA.
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Additional data elements were collected as part of routine
IPC surveillance. Demographic information included the
patient’s date of birth and gender; and other data elements
included admission date, ordering acute care facility, speci-
men site, and whether the specimen was taken as a screen-
ing specimen or as part of clinical work-up. Decisions on
case severity (infection or colonization) are according to
definitions from the National Healthcare Safety Network
(NHSN) [11].
Strain typing
ProvLab performs PFGE as described by Mulvey et al. [1];
PFGE patterns generated were entered into the MRSA
database and analysed using the BioNumerics software
(version 5.1; Applied Maths, Texas, US). PFGE profiles
were grouped into CMRSA epidemic clones according to
the Canadian MRSA classification system [8]. The terms
“traditionally nosocomial” and “traditionally community”
MRSA strains were adapted from Hudson [5] for this study
to denote clones that were originally identified as healthcare
reservoir (i.e., USA100/CMRSA2) or community-associated
(i.e., USA400/CMRSA7 and USA300/CMRSA10).
Polymerase Chain Reaction (PCR) for spa typing was per-
formed using primers targeting the spa gene as previously
described [8, 12, 13]. PCR products were purified using the
ChargeSwitch PCR Clean-up Kit (Invitrogen, Canada) and
sequenced using the BigDye Terminator v3.1 Cycle Sequen-
cing Kit (Life Technologies, Canada). spa typing sequencing
results were analyzed using BioNumerics and submitted to
the online Ridom spa database (http://spaserver.ridom.de/),
developed by Ridom GmbH and curated by SeqNet.org
(http://www.SeqNet.org), for Ridom spa type designation
and assignment of Ridom repeat successions [12].
Data matching and analysis
The IPC data for the 2 year study period between April
2011-March 2013 were extracted and included in the ana-
lysis. The IPC data included incident MRSA cases among
hospitalized patients. Since ProvLab types only one MRSA
clinical isolate per patient in a year from any community
or acute care setting, additional ProvLab data (i.e., from
January 2010-March 2013) were included. The IPC and
the ProvLab data were linked by deterministic matching
in a one-to-many relationship using each patient’s provin-
cial healthcare number, last name, first name, and date of
birth. The ProvLab clinical isolate nearest in date to the
incident IPC case identified from a hospital-collected clin-
ical or screening specimen was selected for analysis
(Fig. 1). An incident IPC screening case identified from a
screening specimen was included if the patient had any
clinical specimen that was sent for molecular testing in
the preceding year. Thus, all IPC-ProvLab matched data
represent MRSA typing results from a clinical specimen.
A Minimum Spanning Tree (MST) of MRSA spa types
observed at least five times in Alberta for the IPC-matched
data was constructed using BioNumerics (Fig. 2). Cluster
analysis was performed using the duplications, substitu-
tions, indels (DSI) algorithm in BioNumerics with the fol-
lowing parameters: 250 % gap creation cost; 50 % gap
extension, duplicate creation and duplicate extension costs;
maximum three repeat duplication; and 1.00 % bin group-
ing distance. Each circle in Fig. 2 represents a different spa
type and similarity values between spa types are shown
adjacent to the connecting lines. IPC case classifications as-
sociated with each spa type are shaded as indicated in the
figure legend.
Data were analyzed using STATA/IC 10.0 (StataCorp,
Texas, 2007). Univariate comparisons of proportions were
performed for categorical variables and the Student’s t test
for continuous variables. MRSA rates were calculated by
dividing the number of incident HA-MRSA cases by the
total hospital patient-days per year per 10,000; and CA and
HCA-MRSA cases by the hospital admissions per year per
1000 as per IPC rate reporting conventions [14]. For all
statistical comparisons a p-value < 0.05 was deemed statisti-
cally significant.
Results
Rates were stable across the study period: the provincial
HA-MRSA rates were 3.1 per 10,000 patient-days in
2011–12 and 2.8 per 10,000 patient-days in 2012–13; the
provincial HCA-MRSA rates were 1.8 per 1000 admis-
sions in both years; and the provincial CA-MRSA rates
were 2.5 per 1000 admissions in both years. MRSA cases
are detected primarily through patient screening: 67.4 %
(3249/4818) of all isolates were detected by screening
swabs (i.e., nares/groin/axilla). See Table 1 for case
counts of HA, HCA and CA-MRSA.
ProvLab typing data were available for 46.7 % (2248/
4818) of incident IPC cases. Those MRSA cases acquired
outside Alberta (n = 37) were not included in this analysis.
Of the IPC-ProvLab matched cases (n = 2211), 34.8 % were
classified as HA, 25.0 % as HCA and 40.2 % as CA-MRSA.
The IPC data were compared to the sub-set of IPC-
ProvLab matched data to see how well the matched data
represented the IPC surveillance data (Table 1). The data
were stratified based on the origin of the incident IPC case
(clinical or screening specimen), however all patients in the
IPC-ProvLab matched data had MRSA typing results from
a clinical specimen even when the incident IPC case was
from a screening specimen. Eighty-eight per cent (1393/
1569) of the IPC clinical specimens had a match in the
ProvLab data. Clinical specimens in the matched and un-
matched data sets therefore had no significant differences
in gender, age, IPC classification or specimen type. Most of
these specimens were deemed infections (91 % in both the
matched and unmatched data sets) according to NHSN
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definitions. For the screening data, 25.2 % (818/3249) of the
IPC data had a match in the ProvLab data. These patients
were younger and more likely to be CA according to the
IPC surveillance definitions.
Figure 2 displays the genetic relationships among spa
types detected at least five times in the IPC-ProvLab
matched data. Isolates belonging to the same epidemic clone
clustered together and clear distinctions are observed be-
tween them. Four spa types comprise 73.2 % of all isolates:
t002 (USA100/CMRSA2, 698/2211, 31.6 %), t008 (USA300/
CMRSA10, 647/2211, 29.3 %), t003 (USA100/CMRSA2,
165/2211, 7.5 %) and t128 (USA400/CMRSA7, 107/2211,
4.8 %) were the most common in the matched data.
The relationship of specific spa types to PFGE nomen-
clature and IPC classification are displayed in Fig. 3 with
additional data provided in the Appendix. The “Other spa
types” category for each PFGE type are a heterogeneous
mix,. For example, the CMRSA2 “Other spa types” com-
prise 10 % of this clone with more than 40 unique spa types
present in this category. The same is true for USA300/
CMRSA10, where 28 spa types are identified for 76 isolates.
Sixty-five percent of HA-MRSA were primarily traditional
Fig. 1 Data analysis flowchart
Fig. 2 Minimum Spanning Tree of MRSA spa types observed at least 5 times
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nosocomial MRSA, with spa type t002 (316/501, 63.1 %)
being most common. CA-MRSA were primarily traditional
community MRSA (554/888, 62.4 %). The HCA category,
denoting other healthcare risks, was a mix of traditional
nosocomial and traditional community MRSA. There was
discordance seen for IPC-defined HA-MRSA with trad-
itional community MRSA (USA400/CMRSA7 and USA30
0/CMRSA10, 207/770, 26.9 %) and for IPC-defined CA-
MRSA with traditional nosocomial (USA100/CMRSA2,
270/888, 30.4 %).
Discussion
In this paper, we describe the molecular epidemiology of
MRSA cases in acute care patients detected by an extensive,
collaborative surveillance network in the Canadian province
of Alberta. Surveillance for healthcare-associated infections
such as MRSA is deemed an essential component of any
IPC program and is included as a required organizational
practice for Canadian healthcare systems [15]. The Public
Health Agency of Canada notes that a region-wide database
is needed to identify and track healthcare-associated infec-
tion trends as patients move between healthcare facilities
and healthcare settings [16]. This type of surveillance
however, requires effective Infection Control Professionals
that cooperate and communicate among the various set-
tings and facilities to ensure standardized data collection,
analysis, and interpretation methods so that the reported
rates and estimated costs of healthcare-associated infec-
tions are reliable. With the formation of a single health
delivery entity in 2009, all provincial hospital IPC surveil-
lance programs consolidated to a single provincial pro-
gram. This surveillance system is centered on a web-based
data entry platform that enables patient-level data to be
available to Infection Control Professionals for patient
Table 1 Comparison of all IPC MRSA cases to IPC-ProvLab matched data
April 2011 – March
2013 n(%)
All IPC MRSA data IPC-ProvLab matched data p value*











Male 825 (52.6) 1699 (52.3) 724 (52.0) 446 (54.5)
Age (Years) < 0.05
Mean Age (±SD) 57 (25.4) 66 (22.8) 56 (25.1) 63 (22.6)
Median Age (IQR) 61 (18.1) 73 (11.4) 59 (18.2) 67 (14.9)
Case Classification
Hospital Acquired 645 (41.1) 1077 (33.1) 578 (41.5) 192 (23.5) < 0.01**
Healthcare 326 (20.8) 978 (30.1) 277 (19.9) 276 (33.7) < 0.04**
Associated
Community Acquired 598 (38.1) 1194 (36.7) 538 (38.6) 350 (42.8) < 0.01**
Facility Bed Size
>500 681 (43.4) 1847 (56.8) 621 (44.6) 460 (56.2) 0.75
251–500 285 (18.2) 495 (15.2) 245 (17.6) 144 (17.6) 0.1
100–250 233 (14.9) 334 (10.3) 210 (15.1) 87 (10.6) 0.76
<100 370 (23.6) 573 (17.6) 317 (22.8) 127 (15.5) 0.15
Severity
Infected 1432 (91.3) n/a 1274 (91.5) n/a 0.86
Clinical Culture Site
Blood 142 (9.1) n/a 130 (9.3) n/a 0.79
Other Sterile 89 (5.7) 88 (6.3) 0.45
Skin/Soft Tissue 947 (60.4) 830 (59.6) 0.67
Infected Device 35 (2.2) 29 (2.1) 0.78
Respiratory 193 (12.3) 172 (12.3) 0.97
Urine 163 (10.4) 144 (10.3) 0.96
All incident IPC MRSA cases can be identified from clinical and screening isolates. Matched clinical isolates from the ProvLab data repository were used as the
surrogate molecular type for IPC cases identified from “screening” cultures
*Tests of significance compare the “screening” populations, except for Clinical Culture site data
**Bonferroni correction adjusted level of significance (α = 0.017) used to consider multiple comparisons with mutually exclusive groups
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management purposes. Standardized provincial surveil-
lance definitions maintain data consistency, enable facil-
ities to benchmark, and allows for comparisons of disease
trends over time. These, in turn, are used to help create a
safer and healthier environment for patients and their
families, and healthcare providers.
The IPC-ProvLab matched specimens where the incident
IPC case was from a clinical specimen represents the ma-
jority of clinical specimens in the IPC data. When IPC iden-
tified an incident MRSA case from a screening specimen,
the IPC-ProvLab matched dataset was able to find a clinical
MRSA isolate within the year of the IPC case presentation.
The ProvLab testing protocol assumes stability in the pa-
tient’s MRSA clone, so that the MRSA from a screening
specimen is assumed to be the same clone as the one typed
from a clinical isolate within the preceding year. There is
support for this testing assumption in the literature, with
duration of MRSA colonization of more than 200 days de-
scribed [17]. In a recent longitudinal evaluation of MRSA
colonized patients with an average of five MRSA isolates
over an average of 251 days, there was 85.7 % genetic con-
cordance seen within patients’ individual isolates [18].
It is important to consider both the epidemiologic defin-
ition as well as molecular typing when classifying MRSA
in the healthcare setting to understand MRSA transmis-
sion dynamics. Laboratory testing using spa typing is use-
ful because of its high concordance with PFGE epidemic
types and allows international comparisons to be made,
rather than relying on naming differences between Canad-
ian, European, US and other naming conventions [8].
In our data, acute care patients who have a clinical isolate
detected as positive in the community rather than during
their acute care admission are younger and more likely to
be identified as CA or HCA in the IPC data, since they
may have already been identified in their patient record as
MRSA positive and therefore screened on admission to the
facility. Traditional community MRSA strains were first
observed as community infections in Canada in the mid-
1990’s. MRSA isolated from sentinel Canadian acute care
sites from 1995 to 2007 showed USA300/CMRSA10 as the
second most commonly isolated clone (27 % of isolates),
with the majority seen in Western Canada [3]. An Alberta
study from 2005 to 2008 confirmed this increase in
USA400/CMRSA7 and USA300/CMRSA10 clones: the
Fig. 3 IPC MRSA case classification and spa type distribution
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highest rates of USA300/CMRSA10 were reported in
people aged 25–44, while highest rates of USA100/
CMRSA2 were seen in patients >65 years [4]. The distri-
bution of the most commonly isolated spa types were
t002, t008, and t128 and they belonged to PFGE epidemic
types USA100/CMRSA2, USA300/CMRSA10, and USA40
0/CMRSA7 respectively [4]. Our data were similar with
t002 (31.6 % of all spa types), t008 (29.3 %), t003 (7.5 %)
and t128 (4.8 %) being the predominant spa types. In the
MST (Fig. 2) we have separated the spa types observed in
hospitalized patients into categories to show the clustering
of both the traditional nosocomial spa types and of the
traditional community spa types, demonstrating the phylo-
genetic diversity with the Alberta MRSA strains. Trad-
itional community spa types further cluster into USA400/
CMRSA7 and USA300/CMRSA10 epidemic types, and the
evolutionary dynamics between closely related spa types
can be inferred.
We used the terminology of “traditional nosocomial” and
“traditional community” to explore the mixing of MRSA
clone reservoirs in relationship to the case classifications
used in IPC surveillance definitions (HA, HCA and CA-
MRSA) [5]. In Alberta, these are assigned based on the tim-
ing of the incident MRSA specimen in respect to the
patient’s admission date or suspected epidemiological links
in the acute care facilities. We noted agreement in defini-
tions for traditional nosocomial clones (USA100/CMRSA2)
with HA-MRSA (65.1 % of all HA-MRSA) and traditional
community clones (USA400/CMRSA7 and USA300/CMRS
A10) with CA-MRSA (62.4 % of all CA-MRSA). However,
we observed discordance for both traditional nosocomial/
CA-MRSA (30.4 % of CA-MRSA strains) and for trad-
itional community/HA-MRSA (26.9 % of HA-MRSA
strains). These findings are the focus of further study to in-
vestigate patients with traditional nosocomial/CA-MRSA;
this may highlight areas for revisions of both the provincial
IPC and national case classifications and surveillance defi-
nitions. For patients with traditional community/HA-
MRSA, further work may highlight issues with admission
screening guidelines in acute care facilities across the prov-
ince and phylodynamic studies may identify clusters of en-
demic traditional community MRSA strains in our acute
care facilities, as has been reported in other settings [6].
Understanding these populations better will inform stan-
dardized MRSA screening guidelines for all acute care ad-
missions in the province as well as providing insights into
the most effective prevention strategies in the healthcare
setting.
Study strengths
This study is unique since all acute care facilities are repre-
sented: including tertiary, smaller urban facilities as well as
small remote rural locations. Because of the integrated na-
ture of the IPC surveillance network, patient transfers are
monitored across all facilities and a patient is only counted
once in the surveillance network. All clinical isolates in the
province are submitted to the ProvLab for molecular test-
ing since June 2005. ProvLab holds a comprehensive la-
boratory based MRSA data repository, with data collated
from submitting acute care laboratories. This is a unique
opportunity to look at two separate standardized surveil-
lance systems exploring complementary aspects for en-
hanced and integrated MRSA surveillance.
Study limitations
Admission screening for MRSA is based on provincial
guidelines [9], however facilities may devise screening strat-
egies based on local MRSA epidemiology; so, all patients
may not have an equal chance of being detected on admis-
sion to an acute care facility. Patients may be identified as
HA-MRSA during their admission or may remain un-
detected and misclassified as CA-MRSA at some time more
than 12 months after their first healthcare encounter. In
addition, the proportion of colonization is influenced by
variation in patient screening practices which may account
for some differences in HA-MRSA rates between the facil-
ities. Work is underway in the province to standardize
MRSA screening and monitor compliance with those
guidelines, however the exact compliance with current
guidelines is not known.
While decision on infection was made using NHSN defi-
nitions [11], the majority of clinical specimens were deter-
mined to be infected. On-going data quality assessment
and education on the use of the definitions is continuing;
however there may have been over-call of infection in these
data. We do not have information on how culturing prac-
tices for infections differ between sites, but our presump-
tion is that they are similar since healthcare is provided in
the same way across the province and many patient care
best practices are standardized across all facilities.
Only the first clinical isolate per year is submitted by a re-
gional laboratory for typing at ProvLab. Therefore a patient
could acquire another MRSA clone within the year and this
would not be identified. ProvLab does not type screening
isolates so typing data were not available for incident IPC
cases from screening specimens, and this study cannot rule
out the possibility of a patient having colonization and in-
fection with different MRSA strains.
Conclusions
The molecular epidemiology of MRSA cases in acute care
patients as detected by an extensive, collaborative surveil-
lance network in the Canadian Province of Alberta. We
note agreement between traditional nosocomial clones and
HA-MRSA, and traditional community clones and CA-
MRSA. However, approximately one-quarter of HA-MRSA
are those of traditional community clones while approxi-
mately one-third of CA-MRSA are those of traditional
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nosocomial clones. Collaborative provincial MRSA surveil-
lance is important as the distinction between IPC case
attribution in acute care settings and the historical defi-
nitions of MRSA clones as community- or healthcare-
associated have blurred and the original labels of
“nosocomial” and “community” for molecular clones of
MRSA are no longer correct in our setting. Further
collaborations between IPC Surveillance-ProvLab teams
will focus on the relationships between genetic types
and IPC surveillance case classifications, in particular
those cases where there is discordance between IPC
case classification definitions and traditional settings of
MRSA types. This work will highlight the need for ef-
fective IPC interventions in the community to reduce
entrance of traditional community MRSA into hospital,
as well as informing acute care interventions for pa-
tients around patient screening and additional isolation
precautions.
Appendix
IPC-ProvLab matched data showing spa type distribution
of traditional nosocomial and traditional community
Table 2 MRSA case classification and molecular epidemiology
Matched MRSA April 2011 – March 2013
n = 2211
Hospital Acquired (HA)
n = 770 (34.8 %)
Healthcare Associated (HCA)
n = 553 (25.0 %)
Community Acquired (CA)















t002 (CMRSA 2) 501 (65.1) 316 (63.1) 327 (59.1) 201 (61.5) 270 (30.4) 181 (67.0)
t003 (CMRSA 2) 72 (14.4) 65 (19.9) 28 (10.4)
t242 (CMRSA 2) 37 (7.4) 24 (7.3) 17 (6.3)
t014 (CMRSA 2) 9 (1.8) 9 (2.8) 7 (2.6)




n = 25 spa types
20 (6.1)
n = 14 spa types
31 (11.5)
n = 22 spa types
Traditional Community
n = 943
t008 (CMRSA 10) 160 (20.8) 128 (80.0) 152 (27.5) 131 (86.2) 445 (50.1) 388 (87.2)
t024 (CMRSA 10) 7 (4.4) 4 (2.6) 9 (2.0)




n = 8 spa types
13 (8.9)
n = 13 spa types
42 (9.4)
n = 24 spa types
t128 (CMRSA7) 47 (6.1) 25 (53.2) 30 (5.4) 19 (63.3) 109 (12.3) 63 (57.8)
t1787 (CMRSA7) 3 (6.4) 6 (20.0) 17 (15.6)








n = 7 spa types
Others n = 170 t065 (CMRSA1) 2 (0.3) 2 (100.0) 9 (1.6) 4 (44.4) 3 (0.3) 2 (66.7)
Other CMRSA1
spa types





t037 (CMRSA3/6) 11 (1.4) 11 (100.0) 2 (0.4) 2 (100.0) 6 (0.7) 6 (100.0)
CMRSA4 spa types 2 (0.3) 2 (100.0)
n = 2 spa types
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
CMRSA5 spa types 1 (0.1) 1 (100.0)
(spa type t064)
1 (0.2) 1 (100.0)
(spa type t064)
1 (0.1) 1 (100.0)
(spa type t1476)
t022 (CMRSA8) 31 (4.0) 10 (32.2) 19 (3.4) 9 (47.4) 12 (1.4) 1 (8.3)




n = 6 spa types
7 (36.8)
n = 4 spa types
9 (75.0)
n = 7 spa types
t019 (PFGE Not
Assigned)




n = 11 spa types
13 (100.0)
n = 11 spa types
25 (59.5)
n = 16 spa types
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MRSA clones by PFGE profile and by IPC case classifica-
tion categories. This table supplements information pro-
vided on specific spa types in Fig. 3.
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